statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Forecasting The Future: 4 Analyst Projections For Cue Biopharma

Latest Ratings for CUE
 DateFirmActionFromTo Nov 2020BerenbergInitiates Coverage OnBuy May 2020StifelMaintainsBuy May 2020OppenheimerMaintainsOutperform
 View More Analyst Ratings for CUE...

Cue Biopharma to Host Business Update Call and Webcast

BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate...

Navalign LLC Takes $66,000 Position in Cue Biopharma, Inc. (NASDAQ:CUE)

Navalign LLC bought a new stake in shares of Cue Biopharma, Inc. (NASDAQ:CUE  Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities  Exchange...

Jefferies Financial Group Begins Coverage on Cue Biopharma (NASDAQ:CUE)

Jefferies Financial Group assumed coverage on shares of Cue Biopharma (NASDAQ:CUE  Free Report) in a research report released on Wednesday, MarketBeat reports. The firm issued a buy rating and...

Cue Biopharma presenting data on lead clinical asset CUE-101 at symposium

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Cue Biopharma's Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium

BOSTON, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate...

Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

BOSTON, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate...

Sigma Planning Corp Boosts Holdings in Cue Biopharma, Inc. (NASDAQ:CUE)

Sigma Planning Corp increased its holdings in Cue Biopharma, Inc. (NASDAQ:CUE  Free Report) by 8.6% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund...

Cue Biopharma, Inc. (NASDAQ:CUE) Sees Significant Growth in Short Interest

Cue Biopharma, Inc. (NASDAQ:CUE  Get Free Report) saw a significant growth in short interest during the month of January. As of January 15th, there was short interest totalling 3,650,000...

Short Interest in Cue Biopharma, Inc. (NASDAQ:CUE) Expands By 5.2%

Cue Biopharma, Inc. (NASDAQ:CUE  Get Free Report) saw a large increase in short interest in December. As of December 31st, there was short interest totalling 3,420,000 shares, an increase of...

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its pipeline includes Immuno-oncology, CUE-100 framework, CUE-200 framework, and autoimmune disease. The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA.

Volume	421,836.00
52-Wk High	$3.90
52-Wk Low	$0.681

CUE Cue Biopharma Inc

About

Feed

News

Sentiment

Earnings

Fundamentals